All Outputs (7)

TIGA-CUB – manualised psychoanalytic child psychotherapy versus treatment as usual for children aged 5–11 years with treatment-resistant conduct disorders and their primary carers: study protocol for a randomised controlled feasibility trial (2017)
Journal Article
Edginton, E., Walwyn, R., Burton, K., Cicero, R., Graham, L., Reed, S., Tubeuf, S., Twiddy, M., Wright-Hughes, A., Ellis, L., Evans, D., Hughes, T., Midgley, N., Wallis, P., & Cottrell, D. (2017). TIGA-CUB – manualised psychoanalytic child psychotherapy versus treatment as usual for children aged 5–11 years with treatment-resistant conduct disorders and their primary carers: study protocol for a randomised controlled feasibility trial. Trials, 18(1), Article 431. https://doi.org/10.1186/s13063-017-2166-2

Background: The National Institute for Health and Care Excellence (NICE) recommends evidence-based parenting
programmes as a first-line intervention for conduct disorders (CD) in children aged 5–11 years. As these are not
effective in 25–33% of cases... Read More about TIGA-CUB – manualised psychoanalytic child psychotherapy versus treatment as usual for children aged 5–11 years with treatment-resistant conduct disorders and their primary carers: study protocol for a randomised controlled feasibility trial.

Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study (2017)
Journal Article
Noon, A. P., Chahal, R., Dooldeniya, M., Koenig, P., Catto, J. W. F., Oughton, J. B., Poad, H., Twiddy, M., Collinson, M., Hiley, V., Gordon, K., Johnson, M., Jain, S., Noonan, A. P., Chalal, R., Simms, M., Dooldynia, M., Koening, P., Goodwin, L., Brown, J. M., & Catto, J. (2017). Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. BMJ open, 7(8), e017913. https://doi.org/10.1136/bmjopen-2017-017913

Introduction High-risk non-muscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease that can be difficult to predict. While around 25% of cancers progress to invasion and metastases, the remaining majority of tumours remain within the blad... Read More about Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.

Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach (2017)
Journal Article
Vargas-Palacios, A., Meads, D. M., Twiddy, M., Murray, C. C., Hulme, C., Mitchell, E. D., Gregson, A., Stanley, P., & Minton, J. (2017). Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach. The journal of antimicrobial chemotherapy, 72(8), 2392-2400. https://doi.org/10.1093/jac/dkx123

© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. Objectives: In the UK, patients who require intravenous antimicrobial (IVA) treatment may receive this in th... Read More about Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach.

NIHR Liver/Renal Biomarker Programme Final Report: Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease (2017)
Report
Selby, P., Banks, R., Gregory, W., Hewison, J., Rosenberg, W., Altman, D., Deeks, J. J., McCabe, C., Parkes, J., Sturgeon, C., Thompson, D., Twiddy, M., Bestall, J., Bedlington, J., Hale, T., Dinnes, J., Jones, M., Lewington, A., Messenger, M. P., Napp, V., …Hutchinson, M. (2017). NIHR Liver/Renal Biomarker Programme Final Report: Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease. Southampton: NIHR

Protein biomarkers are naturally occurring substances that can be measured, often in fluids such as blood or urine, and which provide information about a patient and their illness. Different diseases have different biomarkers. When people become ill,... Read More about NIHR Liver/Renal Biomarker Programme Final Report: Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease.

Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review (2017)
Journal Article
Murray, C. C., Mitchell, E. D., Czoski Murray, C., Meads, D., Minton, J., Wright, J., & Twiddy, M. (2017). Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review. BMJ open, 7(4), Article e013560. https://doi.org/10.1136/bmjopen-2016-013560

OBJECTIVE:
Evaluate evidence of the efficacy, safety, acceptability and cost-effectiveness of outpatient parenteral antimicrobial therapy (OPAT) models.
DESIGN:
A systematic review.
DATA SOURCES:
MEDLINE, EMBASE, CINAHL, Cochrane Library, National He... Read More about Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.

The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence (2017)
Journal Article
Edmondson, A. J., Birtwistle, J. C., Catto, J. W., & Twiddy, M. (2017). The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence. Journal of cancer survivorship : research and practice, 11(4), 453-461. https://doi.org/10.1007/s11764-017-0603-6

© 2017, The Author(s). Purpose: Bladder cancer (BC) is a common disease with disparate treatment options and variable outcomes. Despite the disease’s high prevalence, little is known of the lived experience of affected patients. National patient expe... Read More about The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence.

The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy (2017)
Journal Article
Minton, J., Murray, C. C., Meads, D., Hess, S., Vargas-Palacios, A., Mitchell, E., Wright, J., Hulme, C., Raynor, D. K., Gregson, A., Stanley, P., McLintock, K., Vincent, R., & Twiddy, M. (2017). The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy. Health Services and Delivery Research, 5(6), 1-272. https://doi.org/10.3310/hsdr05060

Background

Outpatient parenteral antimicrobial therapy (OPAT) is widely used in most developed countries, providing considerable opportunities for improved cost savings. However, it is implemented only partially in the UK, using a variety of servi... Read More about The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy.